Canada’s Top 10 Biotech Companies of 2026 By Funding

Congruence Therapeutics, Aspect Biosystems and Helus Pharma lead our 2026 ranking of Canadian biotechs, which scores companies on how much funding they raised or secured this year and what that capital has bought them.

Canada’s biotech sector in 2026 is being shaped by venture rounds, government-backed programs, pharma partnerships, clinical-stage progress and new tools for the life sciences. Each company below is scored on four measures: 2026 funding, clinical or commercial progress, pharma or strategic validation, and funding round quality (weights are listed at the end).

This is our editorial assessment, not an independently published industry ranking. The ranking covers funding events announced or secured from 1 January to 31 October 2026. Seven of the ten companies are private; three (Helus Pharma, NervGen Pharma and Edesa Biotech) are publicly listed, clinical-stage companies. Three entries (Scispot, DropGenie and Qidni Labs) develop research tools, software or devices rather than drug therapeutics. Avivo Biomedical and Qidni Labs appear mainly on the strength of government contributions rather than venture equity. The list uses a broad Canadian life-sciences scope: companies with a meaningful Canadian operating, research, founding or project presence are considered, including enabling-technology businesses.

The ranking at a glance

Funding comparability note. The funding column records the principal 2026 event, not a like-for-like measure of cash received. Equity offerings, venture rounds and government grants or contributions are identified separately. Where a government award is stated as “up to” a maximum amount, it is treated as a commitment ceiling rather than proof that the full amount has been disbursed. ATM authorisations are not counted as proceeds unless shares have actually been sold.

1. Congruence Therapeutics

Overall score: 84.0/100 | Primary strength: Substantial disclosed private financing, backed by pharma validation

Company overview. Congruence is a Montreal company founded in 2021 by Dr Clarissa Desjardins, its CEO, who previously founded Clementia (sold to Ipsen for US$1.3 billion in 2019). Its Revenir platform models how proteins move to find hidden binding pockets, which it uses to design small-molecule “correctors” for protein-misfolding diseases. The company is private and does not publish an employee count.

R&D and funding. R&D spend is not disclosed. Congruence raised a US$50M Series A in February 2022 (extended to more than US$65M in March 2023), a US$32M round in September 2025 and a US$39.5M financing in March 2026.

Key innovation areas. The lead candidate, CGX-926, is an oral MC4R corrector in a Phase 1/1b trial for MC4R-deficient genetic obesity. Two further candidates are in IND-enabling work: one for GBA1-driven Parkinson’s disease and one for alpha-1 antitrypsin deficiency. Ono Pharmaceutical began an oncology research collaboration with Congruence in December 2024 and expanded it to neurology and immunology in March 2026. Ono funds the research and holds an option on resulting compounds; financial terms are undisclosed.

Recent developments. The Ono collaboration was expanded on 2 March 2026. On 19 March, Congruence closed US$39.5M, co-led by Dimension and OrbiMed with Amplitude Ventures, FSTQ, Lumira, Investissement Québec, BDC Thrive, Driehaus and Silver Arc. Proceeds fund the CGX-926 trial and the IND-enabling work.

Future outlook. Congruence guides to CTA/IND filings for the Parkinson’s and alpha-1 antitrypsin candidates in early 2027. It has given no readout date for CGX-926.

2. Aspect Biosystems

Overall score: 76.0/100 | Primary strength: Government and pharma backing for a bioprinted cell-therapy platform

Company overview. Aspect is a Vancouver spinout of the University of British Columbia, led by founder and CEO Tamer Mohamed. It describes a full-stack platform combining AI-powered bioprinting, therapeutic cells, hypoimmune engineering and biomaterials. The federal release on its 2026 funding says the project would maintain 117 jobs and create 283. Aspect is private.

R&D and funding. R&D spend is not disclosed. Capital includes a US$115M Series B (January 2025, led by Dimension with Novo Nordisk participating) and, in July 2024, government funding of C$49M from the federal government and C$23.75M from British Columbia toward a C$200M project. In 2026, the federal Strategic Response Fund committed C$79M toward a C$280M project.

Key innovation areas. Aspect is developing an allogeneic islet-replacement therapy for type 1 diabetes designed to work without chronic immunosuppression, plus other endocrine and metabolic programs. Third-party data lists the lead program as preclinical. A 2023 Novo Nordisk deal provides US$75M in initial payments and up to US$650M in milestones per product for up to four products, plus royalties.

Recent developments. On 20 January 2026, Aspect took over Novo Nordisk’s stem-cell islet and hypoimmune technologies, with a further Novo equity investment plus royalties and milestones; financial terms are undisclosed. On 2 April, the federal C$79M commitment was announced, with about 400 jobs tied to the project. On 28–29 April, Aspect appointed Mike Scott as Chief Development Officer. The April release also cites C$23.8M from British Columbia, which matches the 2024 contribution, so it is not counted as new 2026 funding.

Future outlook. Aspect gives no dated milestones. It says only that it is moving programs toward clinical development.

3. Helus Pharma (formerly Cybin)

Overall score: 71.0/100 | Primary strength: Phase 3 psychedelic-derived depression program with a well-funded balance sheet

Company overview. Helus was founded as Cybin in 2019 and rebranded on 5 January 2026, when it also moved from NYSE American to Nasdaq (HELP); it also lists on Cboe Canada. Its press releases are datelined New York and Toronto, and a headquarters address and employee count are not publicly confirmed. The company develops serotonergic agonists designed to promote neuroplasticity and reports more than 350 patent filings, over 100 of them granted.

R&D and funding. Research expense was US$30.8M in the first quarter of fiscal 2027 (three months to 30 June 2026), double the US$15.0M a year earlier. Net loss for the quarter was US$47.8M, and cash stood at US$166.4M at 30 June 2026. The fiscal year ends 31 March.

Key innovation areas. HLP003 is in the Phase 3 PARADIGM program for adjunctive major depressive disorder, with FDA Breakthrough Therapy Designation and three studies (APPROACH, EMBRACE and EXTEND). HLP004 is in Phase 2 for generalized anxiety disorder. HLP005 is preclinical and heading toward a development candidate.

Recent developments. On 5 March 2026, Helus reported HLP004 Phase 2 topline data in 36 patients: the 20 mg arm cut HAM-A scores by a mean 10.4 points at Week 6, with a 59% response rate, 32% remission and no drug-related serious adverse events. On 28 April it announced a collaboration with TARA Mind to support PARADIGM recruitment. On 25 June it closed a US$50M underwritten offering. On 21 July, APPROACH completed enrolment at 223 participants. The company also named a new CEO during the quarter.

Future outlook. Helus guides to APPROACH topline data in the fourth quarter of 2026, an HLP005 development candidate in the second half of 2027 and a potential FDA NDA filing for HLP003 in 2028.

4. NervGen Pharma

Overall score: 70.0/100 | Primary strength: Pivotal-stage spinal cord injury program with funding through the readout

Company overview. NervGen is a Vancouver company (head office at 970 Burrard Street), incorporated in British Columbia in 2017. Its lead, NVG-291, is a subcutaneous neuroreparative peptide that targets the CSPG-PTPσ pathway. NervGen began trading on Nasdaq (NGEN) on 8 January 2026 and voluntarily delisted from the TSX Venture Exchange effective 16 March 2026.

R&D and funding. R&D expense in the second quarter of 2026 was C$7.8M (restated from C$7.9M), against C$2.7M a year earlier. Cash was C$86.8M at 30 June 2026, up from C$22.1M at 31 December 2025, and the company says this funds operations through the RESTORE topline readout in the first half of 2028. NervGen filed an amended MD&A that restated results for warrant and option valuation errors and disclosed a material weakness in internal controls.

Key innovation areas. NVG-291 has FDA Fast Track and EMA Orphan designations. The Phase 3 RESTORE study in chronic cervical motor-incomplete spinal cord injury plans about 150 participants, randomized 1:1 for 12 weeks, with GRASSP Quantitative Prehension as the primary endpoint. In the earlier CONNECT SCI Phase 1b/2a study (November 2025), improvement on that measure at Week 16 was 3.7 times that of placebo. NVG-300 is a preclinical follow-on.

Recent developments. In April 2026, the FDA aligned with the company on the RESTORE design at an end-of-Phase 2 meeting. On 21–22 May, NervGen priced a US$60M public offering of 24 million units at US$2.50, each with a US$3.68 warrant. On 2 July it established an at-the-market (ATM) facility with Leerink, allowing it to sell up to US$50M of shares over time. The facility represents potential issuance capacity, not US$50M of proceeds already raised, and is not counted as completed 2026 financing here. On 12 October it announced the first participant dosed in RESTORE.

Future outlook. RESTORE enrolment is guided to complete in the second half of 2027, with topline data in the first half of 2028; an R&D Day is planned for fall 2026. The amended MD&A also refers to an FDA partial clinical hold on NVG-291 for spinal cord injury, without giving a date or reason.

5. Kainova Therapeutics

Overall score: 64.0/100 | Primary strength: Clinical-stage immuno-oncology asset with a government-anchored Series B

Company overview. Kainova, formerly Domain Therapeutics, was founded in 2008, is based in Montréal and has 49 employees. It rebranded on 12 January 2026. Its bioSens-All platform studies GPCRs in their native, dynamic states. Sean MacDonald is CEO. The company also operates in France and Australia and is private.

R&D and funding. Annual R&D spend is not disclosed. BetaKit reports about US$90M in venture capital raised, including a US$42M Series A in 2022, plus nearly US$100M in non-dilutive funding; it is unclear whether the US$90M includes the 2026 Series B.

Key innovation areas. DT-7012, a Treg-depleting anti-CCR8 antibody, is in the Phase I/II DOMISOL trial (NCT06819735), covering monotherapy escalation, a combination with pembrolizumab and a Phase II in selected tumors. The trial began in Australia in October 2025. DT-9046, a biased PAR2 antagonist for inflammation, is at pre-IND stage, and DT-9081 is an EP4 antagonist for solid tumors. Kainova has an earlier GPCR discovery collaboration with Ono Pharmaceutical; its date and any 2026 activity are unconfirmed.

Recent developments. On 10 February 2026, Kainova announced a C$32M Series B first close led by Investissement Québec, with CTI Life Sciences Fund, Panacea Venture, 3B Future Health Fund, Seventure, Viva BioInnovator, Turenne Capital, Schroders Capital, adMare and Seido Capital. On 9 April it dosed the first patient in the European expansion of DOMISOL, with sites in Strasbourg, Paris and Bordeaux. No company announcements after April were identified.

Future outlook. Series B proceeds are to advance DT-7012 and complete preclinical development of DT-9046 in 2026. The CEO called 2026 “pivotal” and said data will come “in the coming quarters”, without dates.

6. Edesa Biotech

Overall score: 50.0/100 | Primary strength: Late-stage immunology assets, recapitalized with about US$28.5M in 2026

Company overview. Edesa is a clinical-stage company headquartered at 100 Spy Court, Markham, Ontario. It is a British Columbia corporation founded in 2007 that took the Edesa name in 2019 through a reverse acquisition of its Ontario operating company. It has 17 full-time employees, 10 of them in R&D, and trades on Nasdaq (EDSA). Pardeep Nijhawan is CEO. Its FY2025 10-K carried a going-concern warning, which predates the 2026 raises.

R&D and funding. R&D expense was US$3.67M in fiscal 2025 (year to 30 September 2025), up from US$2.88M. In the third quarter of fiscal 2026 (to 30 June 2026), R&D was US$4.0M, or US$7.8M for the nine months, and cash was US$10.3M at 30 June, before the August offering. Fiscal 2026 ended on 30 September, and full-year results are not yet published.

Key innovation areas. EB06, an anti-CXCL10 antibody, is in a double-blind Phase 2 study in vitiligo, with F-VASI at Week 28 as the primary endpoint; the October 2026 IND release says up to 80 subjects. Paridiprubart (EB05, anti-TLR4) completed a truncated Phase 3 in ARDS that met its primary and secondary endpoints, and the company is exploring partnering and regulatory pathways. EB01 (daniluromer cream) for allergic contact dermatitis is Phase 3-ready.

Recent developments. On 11 June 2026, Edesa announced a US$3.5M private placement led by its CEO, which its SEC filing says closed on 16 June. On 19 August it priced an underwritten public offering of about US$25M with Guggenheim as sole bookrunner, which closed on 21 August. On 15 October the FDA cleared the EB06 Phase 2 IND, and recruitment is already underway in Canada. Data presented at the June ERA Congress in ARDS patients with acute kidney injury showed adjusted 28-day mortality of 33% versus 49% on placebo, according to a secondary source.

Future outlook. The first US sites are expected to begin enrolling in the quarter after 15 October 2026, with EB06 topline data guided to the fourth quarter of 2027. Edesa has given no formal financial guidance, and the paridiprubart path has no stated date.

7. Scispot

Overall score: 49.0/100 | Primary strength: Commercial traction in AI-native lab software

Company overview. Scispot is a Kitchener-Waterloo, Ontario company that launched roughly five years ago; its founding year is not stated. It is a Y Combinator graduate with a team of about 30. Guru Singh is co-founder and CEO, and Satya Singh is co-founder and CTO. Its website lists offices in Kitchener, Seattle, London, San Francisco and Montreal. Scispot makes lab software rather than drugs.

R&D and funding. R&D spend is not disclosed. BetaKit reports total funding of nearly US$10M, including the US$8M Series A.

Key innovation areas. Scispot’s AI-native “LabOS” can replace or sit alongside ELN, LIMS, LIS, SDMS and QMS systems and supports more than 250 instrument profiles. It covers sample tracking, instrument data, protocol states, audit trails and e-signatures, and connects to AI tools through an MCP server. The stated long-term vision is “self-driving labs”. Its website displays GxP, 21 CFR Part 11, CLIA, ISO 27001, SOC 2 and HIPAA badges, and its efficiency claims are vendor-reported. The company serves more than 100 customers; BetaKit cites 125+, while other coverage cites 100+.

Recent developments. On 4 June 2026, Scispot raised an all-equity US$8M Series A led by Avenue Growth Partners, with existing backer Breakwater Ventures participating. No other dated 2026 announcements were identified.

Future outlook. Most proceeds will fund forward-deployed AI engineers and scientists. Scispot plans to expand commercial services globally, supply structured lab data to AI developers and build a durable business from Canada rather than seek a quick sale. No dates were given.

8. DropGenie

Overall score: 48.0/100 | Primary strength: Pharma-backed gene-editing workflow tool nearing commercial launch

Company overview. DropGenie operates in Montreal and Boston and is led by co-founder and CEO Alison Hirukawa. Its founding year and headcount are not stated. The company builds high-throughput, miniaturized and automated gene-editing workflows that edit primary patient cells directly, aimed at cell therapy, functional genomics and AI-driven discovery.

R&D and funding. R&D spend, total capital raised and the Seed+ amount are all undisclosed. Existing investors are Real Ventures and Anges Québec.

Key innovation areas. The first product is a miniaturized gene-editing workflow, validated through an Early Access Program, that cuts the cells and reagents needed per experiment. The company says many pharma, biotech and research customers are integrating it but names none. It also plans data partnerships with customers to generate standardized gene-editing datasets for AI-driven discovery.

Recent developments. On 22 June 2026, DropGenie closed a Seed+ round led by Skeleton Key, with new investors Merck Global Health Innovation Fund and CQDM. Funds will go to scaling manufacturing, building commercial operations and driving customer adoption.

Future outlook. DropGenie intends to complete the commercial launch of its first product and scale manufacturing, with no dated milestones. Dealroom lists unproven commercial-scale performance and customer adoption as open challenges.

9. Avivo Biomedical

Overall score: 41.0/100 | Primary strength: Peer-reviewed enzyme technology for universal-type organs and blood

Company overview. Avivo, formerly ABOzymes Biomedical, is a Vancouver spinout of the University of British Columbia. One source gives its founding year as 2020 and its headcount as 10–19. Its enzymes convert blood-group antigens to type O, the universal donor type, in blood and organs. Partners include the University of Cambridge, Canadian Blood Services, University Health Network and Mayo Clinic (know-how agreement dated 14 November 2023). Its current CEO is unconfirmed.

R&D and funding. The federal Life Sciences Fund committed up to C$10.9M toward a C$33.9M project, about one third of the cost. The 2022 seed amount and total capital raised are not disclosed. Aggregators list US$7.7M and US$7.8M, but neither figure traces to a primary source.

Key innovation areas. Avivo’s ECO (Enzyme-Converted type-O) work includes a kidney converted from type A to O and transplanted into a brain-dead recipient, published on 3 October 2025 in Nature Biomedical Engineering. There was no hyperacute rejection for two days, then a mild reaction on day three as some markers returned. An earlier lung proof of concept appeared in Science Translational Medicine in February 2022.

Recent developments. On 18 September 2026, Avivo was one of five companies in a C$67M Life Sciences Fund round, for a project to expand blood-transfusion and organ-transplant capability. This is a government contribution, not venture equity.

Future outlook. Avivo says it is advancing toward first-in-human trials. UBC notes that more preclinical work and regulatory approval are needed before trials in living patients. No milestone dates were found.

10. Qidni Labs

Overall score: 41.0/100 | Primary strength: Portable dialysis device with preclinical evidence and a federal contribution

Company overview. Qidni is a private company founded in 2014, according to secondary sources, and is led by founder and CEO Morteza Ahmadi. Its headquarters is unsettled: the company website lists both Buffalo, New York and Kitchener, Ontario, Innovation Factory calls Kitchener its HQ, and several data providers give Buffalo. Employee counts conflict (9 to 20), so its Canadian anchoring is not fully confirmed. The device is a compact, battery-capable, nearly waterless hemodialysis system that uses saline bags and sorbent “Qartridges”, with cloud monitoring. The company’s website says it is not approved by the FDA or Health Canada.

R&D and funding. R&D spend is not disclosed. The federal Life Sciences Fund committed up to C$12.5M toward a C$25M project. PitchBook records a US$5M Series A on 12 August 2025, which no primary release confirms, and total capital raised is reported inconsistently at about US$8.5M. Grants include KidneyX, NRC-IRAP and OBIO.

Key innovation areas. Long-term animal studies are reported complete and pilot clinical studies are starting, according to Innovation Factory (undated). The platform targets home, mobile, emergency and low-resource dialysis. Qidni holds patent US-11964090-B2 on gas removal from a wearable device.

Recent developments. On 18 September 2026, the Life Sciences Fund contribution was announced to finalize the design, support pilot-scale manufacturing in Ontario, fund clinical studies and gather real-world battlefield data. This is a government contribution, not venture equity. No other dated 2026 events were identified.

Future outlook. Qidni has not published dated milestones.

Ranking criteria

Each company was scored out of 100 on four weighted criteria. Scores are editorial assessments based on the evidence available for this report; the published totals are weighted overall scores, not independently audited ratings. Component-level scores are not shown, so readers should treat close score differences as indicative rather than statistically significant.

Companies considered but excluded

We reviewed a wider field of Canadian biotechs and left out the companies below because they lacked a disclosed 2026 financing, did not fit the scope of the list, or were no longer independent.